{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:54:11Z","timestamp":1774288451328,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020703","name":"Department of Pharmaceutical Sciences, St. John's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["SC3GM131971"],"award-info":[{"award-number":["SC3GM131971"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017453","name":"Institute for Prostate Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015616","name":"Gray Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015616","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108941","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T23:25:49Z","timestamp":1757114749000},"page":"108941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors"],"prefix":"10.1016","volume":"165","author":[{"given":"Abosede","family":"Salami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugochi","family":"Adiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griffin","family":"Coate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Diolaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huadong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua S.","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andhavaram","family":"Ramaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akanksha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himaxi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketankumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh V.","family":"Ambudkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanaji T.","family":"Talele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bioorg.2025.108941_bb0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tibs.2009.12.003","article-title":"Toward a unified nomenclature for mammalian ADP-ribosyltransferases","volume":"35","author":"Hottiger","year":"2010","journal-title":"Trends Biochem. Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108941_bb0010","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Ame","year":"2004","journal-title":"Bioessays"},{"issue":"Pt 2) (Pt 2","key":"10.1016\/j.bioorg.2025.108941_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj3420249","article-title":"Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions","volume":"342","author":"D\u2019Amours","year":"1999","journal-title":"Biochem. J."},{"issue":"8\u20139","key":"10.1016\/j.bioorg.2025.108941_bb0020","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.dnarep.2004.06.002","article-title":"PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development","volume":"3","author":"Huber","year":"2004","journal-title":"DNA Repair"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108941_bb0025","first-page":"2546","article-title":"Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin","volume":"45","author":"Hanzlikova","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.108941_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-biochem-060614-034506","article-title":"Nuclear ADP-ribosylation and its role in chromatin plasticity, cell differentiation, and epigenetics","volume":"84","author":"Hottiger","year":"2015","journal-title":"Annu. Rev. Biochem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108941_bb0035","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"15","key":"10.1016\/j.bioorg.2025.108941_bb0040","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1111\/febs.12358","article-title":"The recognition and removal of cellular poly(ADP-ribose) signals","volume":"280","author":"Barkauskaite","year":"2013","journal-title":"FEBS J."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108941_bb0045","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108941_bb0050","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1093\/nar\/gkq1241","article-title":"Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate","volume":"39","author":"Str\u00f6m","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"7381","key":"10.1016\/j.bioorg.2025.108941_bb0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108941_bb0060","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"issue":"7035","key":"10.1016\/j.bioorg.2025.108941_bb0065","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"10.1016\/j.bioorg.2025.108941_bb0070","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"6330","key":"10.1016\/j.bioorg.2025.108941_bb0075","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"9737","key":"10.1016\/j.bioorg.2025.108941_bb0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.bioorg.2025.108941_bb0085","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1021\/jm901188v","article-title":"Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors","volume":"52","author":"Jones","year":"2009","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108941_bb0090","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1158\/1535-7163.MCT-06-0552","article-title":"Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial","volume":"6","author":"Thomas","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108941_bb0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/acs.jmedchem.5b01498","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108941_bb0100","first-page":"1","article-title":"Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)","author":"Velagapudi","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108941_bb0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10549-012-2106-5","article-title":"Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells","volume":"134","author":"Chuang","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108941_bb0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108941_bb0115","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.2147\/CMAR.S200524","article-title":"Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer","volume":"11","author":"Jiang","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108941_bb0120","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","article-title":"Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors","volume":"13","author":"Hopkins","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108941_bb0125","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108941_bb0130","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1172\/JCI120388","article-title":"The evolving landscape of predictive biomarkers of response to PARP inhibitors","volume":"128","author":"Thomas","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108941_bb0135","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1021\/acs.jmedchem.8b01709","article-title":"Design and synthesis of poly(ADP-ribose) polymerase inhibitors: impact of adenosine pocket-binding motif appendage to the 3-oxo-2,3-dihydrobenzofuran-7-carboxamide on potency and selectivity","volume":"62","author":"Velagapudi","year":"2019","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108941_bb0140","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/jm5002502","article-title":"Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors","volume":"57","author":"Patel","year":"2014","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108941_bb0145","doi-asserted-by":"crossref","first-page":"13291","DOI":"10.1021\/acs.jmedchem.0c00829","article-title":"Opportunities for tapping into three-dimensional chemical space through a quaternary carbon","volume":"63","author":"Talele","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6486","key":"10.1016\/j.bioorg.2025.108941_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108941_bb0155","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/ci100036a","article-title":"Test MM-PB\/SA on true conformational ensembles of protein-ligand complexes","volume":"50","author":"Li","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108941_bb0160","doi-asserted-by":"crossref","first-page":"12392","DOI":"10.1080\/07391102.2021.1970629","article-title":"Drug repurposing combined with MM\/PBSA based validation strategies towards MEK inhibitors screening","volume":"40","author":"Thirunavukkarasu","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108941_bb0165","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/jm060522a","article-title":"Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring","volume":"49","author":"Lyne","year":"2006","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108941_bb0170","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1158\/1535-7163.MCT-17-0098","article-title":"Modeling therapy resistance in BRCA1\/2-mutant cancers","volume":"16","author":"Drean","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108941_bb0175","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2133\/dmpk.18.128","article-title":"Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS\/MS method with four probe drugs, midazolam, testosterone","volume":"18","author":"Racha","year":"2003","journal-title":"Nifedipine and Terfenadine. Drug Metab. Pharmacokinet."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108941_bb0180","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1021\/acs.biochem.1c00161","article-title":"Midazolam as a probe for drug-drug interactions mediated by CYP3A4: Homotropic allosteric mechanism of site-specific hydroxylation","volume":"60","author":"Denisov","year":"2021","journal-title":"Biochemistry"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108941_bb0185","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108941_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11171","article-title":"P-glycoprotein and cancer: what do we currently know?","volume":"8","author":"Pilotto Heming","year":"2022","journal-title":"Heliyon"},{"issue":"44","key":"10.1016\/j.bioorg.2025.108941_bb0195","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108941_bb0200","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","article-title":"Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer","volume":"10","author":"Christie","year":"2019","journal-title":"Nat. Commun."},{"issue":"2 Suppl","key":"10.1016\/j.bioorg.2025.108941_bb0205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.taap.2005.03.027","article-title":"P-glycoprotein activity and biological response","volume":"207","author":"Vaalburg","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108941_bb0210","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.4c00603","article-title":"Discovery of a novel [6\u20136\u20135\u20135\u20136] Pentacyclic Tetrahydrocyclopentaphthalazinone as a promising PARP inhibitor scaffold","author":"Doruk","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108941_bb0215","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bioorg.2025.108941_bb0220","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0076-6879(98)92039-0","article-title":"Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells","volume":"292","author":"Ambudkar","year":"1998","journal-title":"Methods Enzymol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108941_bb0225","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2404897","article-title":"Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2","volume":"22","author":"Shukla","year":"2008","journal-title":"Leukemia"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:28:33Z","timestamp":1760560113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"alternative-id":["S0045206825008211"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108941","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108941"}}